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Background: endogenous vasoconstrictor peptides may play a role in the pathophysiology of critical limb ischaemia (CLI).
This study investigated endothelin-1 (ET-1) and urotensin-II (U-II) mRNA expression, peptide distribution and ET
receptor subtype binding in chronically ischaemic muscle.
Methods: open muscle biopsies were taken from patients undergoing amputations for CLI and from patients undergoing
coronary artery bypass surgery (controls). ET-1 and U-II mRNA expression in muscle biopsies was studied using real-time
quantitative reverse transcription-polymerase chain reaction (RT-PCR). ET-1 and U-II immunohistochemistry was per-
formed on muscle sections and ET receptor binding studied using in vitro autoradiography.
Results: ET-1 mRNA expression was significantly increased in CLI compared to controls (p5 0.05) whilst no significant
change in U-II expression occurred. ET-1 immunoreactivity was also increased in CLI with no difference in U-II
immunostaining observed. ETB receptor binding was significantly increased in CLI (median 4, range 1±8 vs 2, range
1±3, dpm6 103/mm2, p 0.01, Mann±Whitney test) whilst ETA receptor binding was not significantly raised. Binding
was associated with microvessels and macrophages.
Conclusions: in CLI, the ET-1 pathway is upregulated but U-II is unaffected. ET-1 may vasoconstrict microvessels and
mediate inflammation in chronically ischaemic muscle. ET-1 binding to ETB receptors in particular may play an important
role in the pathophysiology of CLI underscoring the therapeutic potential of ETB receptor antagonists in the management
of CLI.
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Introduction
Endogenous vasoactive peptides have been found to
play a pathophysiological role in a variety of cardio-
vascular diseases.1,2 In peripheral vascular disease
(PVD), altered vessel tone may contribute to chronic
lower limb ischaemia, suggesting that vasoconstrictor
peptides may play a role in its pathophysiology.
Endothelin-1 (ET-1) is a potent vasoconstrictor pep-
tide3 that has been implicated in ischaemic conditions
such as ischaemic heart disease4,5 and ischaemia-
induced acute renal failure.6 This 21-amino acid
peptide is released by a variety of cells, including endo-
thelial cells, in response to hypoxia, changes in shear
stress, growth factors and vasoactive hormones.7 In
addition to being a potent vasoconstrictor, it also
has proliferative properties and plays a role in
inflammation.8,9 Two main ET-1 receptor subtypes
have been identified: ETA and ETB receptors.
10 ETA
receptors are highly expressed on vascular smooth
muscle cells where ET-1 binding results in vasocon-
striction. ETB receptors on vascular smooth muscle
cells also cause vasoconstriction11 whereas those on
endothelial cells cause vasodilation via the release of
nitric oxide.7 In patients with PVD, raised circulating
and tissue levels of ET-1 have been described.12,13
More recently, urotensin-II (U-II) has been cloned14
and found to be an agonist for the orphan G-protein
coupled receptor GPR14.15 Both U-II and its receptors
are expressed in human cardiac and peripheral vas-
cular tissue.15 There is evidence that U-II may be a
more potent vasoconstrictor than ET-1.15 Although
subsequent studies suggest that its vasoconstrictor
activity may be species and site specific,16±18 U-II
may also play a role in vasomotor tone control in
pathological conditions such as PVD.
This study aimed to investigate the potential role of
ET-1 and U-II in PVD by studying their mRNA
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expression and peptide distribution in normal and
chronically ischaemic muscle. In addition, ETA and
ETB receptor binding was also studied.
Materials and Methods
Patients
Ten patients undergoing primary below-knee amputa-
tions for critical limb ischaemia (CLI) and ten patients
undergoing coronary artery bypass surgery (controls)
with no significant PVD were recruited. The clinical
definition of CLI recommended by the TransAtlantic
Inter-Society Consensus (TASC) on the Management
of Peripheral Arterial Disease19 was used. Significant
PVD was excluded from patients in the control group
by clinical history, examination and ankle: brachial
Doppler indices (ABPI50.9). Local ethics committee
approval and informed consent from patients were
obtained.
The mean age of the CLI group was 71 years (range
48±86 years) with nine males and one female. Two were
smokers. In the control group, the mean age was
69 years (range 57±77 years); all were male and two
were smokers. All surgery was performed under gen-
eral anaesthesia and no vasoactive drugs were given.
Muscle biopsies
Open muscle biopsies were taken from the gastrocne-
mius muscle intra-operatively as soon as it was
adequately exposed. Tissue from all patients was fro-
zen immediately on dry CO2 for immunohistochem-
istry and autoradiography. Tissue was also frozen in
liquid nitrogen for reverse transcriptase-polymerase
chain reaction (RT-PCR) from six patients in each
group and stored at ÿ70 °C. All the laboratory anal-
yses were not performed on every sample due to
limited tissue availability. For immunohistochemistry
and autoradiography, 7 mm serial cryostat sections
were cut at ÿ25 °C and three sections from each
muscle biopsy were sequentially thaw-mounted
onto polylysine-coated microscope slides. Slides
were coded for blind analyses and stored at ÿ70 °C
until used.
ET-1 and U-II mRNA expression
Gene expression was studied using quantitative
reverse transcription-polymerase chain reaction (RT-
PCR) with real-time detection using Taqman1 probes.
Total RNA was isolated from homogenised muscle
biopsies using TRIzol1 reagent (Invitrogen Life Tech-
nologies, Paisley, U.K.) according to the manufac-
turer's instructions. Two mg of RNA from each
sample was treated with RQ1 RNase-free DNase
(Promega, WI, U.S.A.) and then reversed transcribed
into cDNA using random hexamer primers (Roche,
Mannheim, Germany), Moloney murine leukaemia
virus reverse transcriptase (Invitrogen Life Techno-
logies) and deoxyNTP (dNTP mix, Promega) according
to the manufacturer's instructions.
The cDNA sample was then used for real-time
quantitative PCR, performed with the ABI Prism 7700
Sequence Detection System (Perkin-Elmer Applied
Biosystems, CA, U.S.A.) as previously described.20,21
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as the endogenous control. The sequences
for the forward and reverse primers and 6-carboxy-
fluorescein (FAM)-labelled Taqman probes used for
amplification of human ET-1, U-II and GAPDH
mRNA are given in Table 1. The thermal cycling
conditions comprised initial enzyme activation steps
at 50 °C for 2 min 2 and 95 °C for 10 min followed
by 40 cycles of denaturation at 95 °C for 15 s and
annealing/extension at 65 °C for 1 min. Samples were
analysed in triplicate.
Quantitative values were obtained from the thres-
hold cycle number at which an exponential growth of
PCR products was detected (CT). Each sample was
normalised to its content of the endogenous control,
GAPDH (DCT). DCT values were used for statistical
analyses. In addition, results were expressed as N-fold
Table 1. Forward and reverse primer and FAM-labelled Taqman probe sequences used of RT-PCR.
ET-1 U-II GAPDH
Forward primer 50-GCCCTCCAGAGAGCGTTATG-30 50-AAGACGCGCGCTTAACTCC-30 50-CCAGGAAATGAGCTTG
ACAAAGTT-30
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differences in target gene expression between CLI
samples and control biopsies, determined as follows:
N target  2CTsampleÿCTcontrol
Immunohistochemistry
Immunohistochemical identification of ET-1 and U-II
was performed using a monoclonal anti-ET-1 anti-
body (Peninsula Laboratories, St Helens, U.K.) and a
polyclonal anti-U-II antibody (Alpha Diagnostic Inter-
national, TX, U.S.A.) respectively. Monoclonal anti-
bodies against platelet-endothelial cell adhesion
molecule-1 (CD31; DAKO Ltd, Denmark) and CD68
(DAKO Ltd) were used to identify endothelial cells
and macrophages respectively within muscle sections.
Immunohistochemistry was performed using the
avidin-biotin-complex (ABC) peroxidase method.
Sections were allowed to equilibrate to room tempera-
ture, fixed in acetone at ÿ 20 °C for 20 min and rinsed
in PBS. Endogenous peroxidase activity was inhibited
by immersion in 0.5% hydrogen peroxide in methanol
for 10 min and rinsing in PBS. Sections were then
incubated in 5% normal goat serum in PBS at room
temperature for 20 min to block non-specific staining
followed by incubation in primary antibody diluted
(ET-1 1:500, U-II 1:100, CD31 1:200, CD68 1:200) in PBS
for 1 h at room temperature. Sections were then incu-
bated with biotinylated secondary goat antibody for
30 min, followed by incubation in streptavidin/bioti-
nylated horseradish peroxidase for 30 min (DAKO
Ltd). Peroxidase activity was revealed using diamino-
benzidine (DAB). Sections were counterstained with
Mayer's haematoxylin, prepared for microscopic
examination and examined and photographed using
an Olympus BX 50 microscope.
Autoradiography
ET-1 receptors were identified using [125I]-ET-1.22 ETA
and ETB binding sites were assessed using the subtype
selective radioligands [125I]-PD15124223 and [125I]-
BQ302024 respectively.25 Slide-mounted sections were
pre-incubated in 50 mM Tris HCl buffer, pH 7.4 for
15 min at room temperature to reduce endogenous
peptide levels. Sections were then incubated in Tris
HCl buffer (plus 5 mM MgCl2, 0.2% bovine serum
albumin and 100 k.i.u/ml aprotinin) containing 100 to
150 pM [125I]-ET-1 (specific activity 2000 Ci/mmol/L,
Amersham Pharmacia Biotech, Buckinghamshire,
U.K.) or [125I]-PD151242 to assess ETA and [
125I]-
BQ3020 (specific activities 2000 Ci/mmol/L,
Amersham Pharmacia Biotech) to assess ETB binding
sites, for 120 min at room temperature. The degree of
non-specific binding for each radioligand was estab-
lished by incubating alternate slides in the presence of
an excess concentration (1 mM) of unlabelled ET-1
(Bachem Fine Chemicals, Basel, Switzerland). After
incubation tissue was washed in Tris HCl buffer fol-
lowed by distilled water at 4 °C and dried. Autoradio-
graphs were generated by exposing incubated tissue
to Hyperfilm 3H (Amersham Pharmacia Biotech) in
X-ray cassettes for 4 days at 4 °C. Films were then pro-
cessed according to manufacturer's instructions and
used for densitometric analysis of receptor binding
using a Bio-Rad GS-700 imaging densitometer with
Molecular Analyst Software (Bio-Rad Laboratories,
CA, U.S.A.). Binding was expressed in terms of
radioligand bound per unit area (disintegrations
per min (dpm)/mm2), calculated from standard curves
generated by 125I-microscales (Amersham Pharmacia
Biotech) that were co-exposed with tissue sections.
Specific binding was calculated by subtracting non-
specific from total binding.
Microscopic localisation (high-resolution autoradi-
ography) of binding sites was performed by post-
fixing tissue in paraformaldehyde vapour for 2 h at
80 °C and then dipping the slides in molten K2 nuclear
emulsion (Ilford Ltd, Mobberley, Cheshire, U.K.) under
darkroom conditions. Slides were then stored in light-
proof boxes for up to 8 days at 4 °C. Emulsion was pro-
cessed in D19 high contrast developer (Kodak, U.K.)
and fixed (Hypam, Ilford, U.K.), following the manu-
facturer's instructions. Underlying tissue was stained
with Mayer's haematoxylin and eosin for histological
examination. Sections were viewed on an Olympus
BX 50 microscope under bright and dark field illumina-
tion and photographed where appropriate.
Statistical analysis
Results are presented as median values and ranges.
The two-tailed, non-parametric Mann±Whitney test
was performed using Prism 3.02 (GraphPad Software,




Median DCT for ET-1 was 10 (range 9±12) in CLI
biopsies and 12 (range 11±14) in control biopsies,
which relates to a 4-fold increase in ET-1 mRNA in
CLI biopsies (p 0.03) (Fig. 1a).
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U-II mRNA expression
Median DCT for U-II was 17 (12±18) in CLI biopsies
and 17 (range 16±20) in control biopsies, which was
not a significant increase in U-II mRNA (p 0.4)
(Fig. 1b).
ET-1 immunohistochemistry
ET-1 immunoreactivity was identified on muscle
fibres of CLI and control biopsies. In addition,
immunostaining was associated with CD31-positive
microvessels (Fig. 2) and macrophages identified by
CD68 within the biopsies. ET-1 immunostaining was
increased in CLI biopsies (Fig. 3). Microvessels and
macrophages were also more abundant in CLI
biopsies (not shown).
U-II immunohistochemistry
U-II immunostaining of muscle biopsies was
weak with positive immunoreactivity being restricted
to a low number of intrafascicular capillaries and
there was no evidence of increased immunoreactivity
in CLI muscle (not shown).
ET receptor autoradiography
On examination of autoradiographs, binding of [125I]-
ET-1 to both CLI and control biopsies was observed.
Using subtype-selective radioligands, both ETA and
ETB receptors were found to be involved (Fig. 4). On
densitometric analysis, non-specific binding accounted
for less than 15% of total binding. ETB receptor bind-
ing was significantly increased in CLI (4, range 1±8,
dpm 103/mm2) compared to controls (2, range 1±3,
dpm 103/mm2, p 0.01) whereas ETA receptor bind-
ing was not significantly altered (3, range 1±5, vs 3,
range 1±4, dpm 103/mm2, p 0.1) (Fig. 5). In addi-
tion to binding to muscle fibres, discrete clusters of
binding were apparent on film, which were associated
Fig. 1. ET-1 and U-II mRNA expression quantified by real-time
RT-PCR. (a) ET-1 mRNA expression. Median DCT for ET-1 was
10 vs 12 in CLI and control biopsies respectively, p5 0.05,
Mann±Whitney test. This represented a 4-fold increase in ET-1
mRNA in CLI biopsies. (b) U-II mRNA expression. Median
DCTs for U-II were 17 in CLI and control biopsies, p 0.4,
Mann±Whitney test.
Fig. 2. ET-1 immunoreactivity associated with microvessels in muscle biopsies. ET-1 immunoreactivity (left) was associated with CD31
positive microvessels on an adjacent section (right) as well as muscle fibres of a CLI biopsy. DAB was used as the chromagen for both
antibodies. Scale bar 50mm.
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Fig. 3. ET-1 immunoreactivity in muscle biopsies. ET-1 immunoreactivity identified in brown by the chromagen DAB, was higher in CLI
biopsies (middle) compared to control biopsies (left). No immunostaining occurred in negative controls incubated in the absence of primary
antibody (right). Scale bar 25mm.
Fig. 4. Autoradiographs of ET-1, ETA and ETB receptor binding in CLI muscle. Haematoxylin and eosin stained micrograph (top left) and
representative autoradiographs of [125I]-ET-1, [125I]-PD151242 (ETA) and [
125I]-BQ3020 (ETB) total binding to consecutive sections of CLI
muscle biopsy. (Note clusters of ETA and ETB binding.) Scale bar 2.5 mm.
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with microvessels and macrophages on high-reso-
lution autoradiography (Fig. 6).
Discussion
Apart from being a potent vasoconstrictor, ET-1 has
been shown to be mitogenic on a number of different
cell lines including vascular smooth muscle cells.26 It
has also been implicated as an inflammatory mediator,
being a chemoattractant for monocytes, an activator of
macrophages,27 a stimulant for the release of other
inflammatory mediators such as interleukin-628 and
prostaglandins29 as well as possessing the ability to
up-regulate adhesion molecule expression.30 There is
also evidence that ET-1 is an angiogenic factor.8
The vasoconstrictive and mitogenic effects of ET-1
are thought to be primarily mediated via ETA recep-
tors.31,32 ET-1 binding to ETB receptors on vascular
smooth muscle cells also contributes to its vasocon-
strictor activity whilst binding to ETB receptors on
endothelial cells results in vasodilation via the release
of nitric oxide.31 ETB receptors have been shown to
mediate the inflammatory effects of ET-133,34 and
increased ETB receptor expression has been found in
inflammatory cells of atherosclerotic lesions.35 It is less
clear which ET receptor subtype mediates the angio-
genic effects of ET-1 since both ETA
8 and ETB
36,37
receptors have been implicated in different studies.
In this study, increased ET-1 mRNA levels were
found in chronically ischaemic muscle. The ET-1 path-
way was therefore further investigated by studying
the distribution of the peptide and its receptors.
Increased tissue ET-1 peptide levels were observed in
ischaemic muscle and ET receptor subtype binding
occurred in both ischaemic and control muscle biop-
sies. In particular, ETB receptor binding was signifi-
cantly increased in CLI biopsies. ET-1 and its receptors
were associated with microvessels and inflammatory
cells, which were both increased within CLI biopsies.
These findings suggest that increased ET-1 synthesis
occurs in chronically ischaemic muscle where the pep-
tide can act in a paracrine fashion on receptors within
the muscle. Its association with microvessels and
macrophages suggests that ET-1 may activate recep-
tors at these sites to cause vasoconstriction and exacer-
bate inflammation, thus contributing to muscle
damage. Upregulation of ET receptors may therefore
enhance the effect of endogenously released ET-1. The
preferential upregulation of ETB receptors suggests
that this receptor subtype may play a major role in
chronic muscle ischaemia. This receptor distribution is
similar to that described in atherosclerotic lesions
in both human and apoE knock-out mice where
increased ETB receptors were found that were asso-
ciated with macrophages, T-lymphocytes and medial
smooth muscle cells.35,38 In addition, smooth muscle
cells located beneath foamy macrophages exhibited
higher ETB receptor immunoreactivity than those


Fig. 5. Densitometric analysis of ET receptor subtype binding. [125I]-
PD151242 binding to ETA receptors was not significantly increased:
3 vs 3 dpm 103/mm2, p 0.1, Mann±Whitney test. [125I]-BQ3020
binding to ETB receptors was significantly increased in CLI com-
pared to controls: 4 vs 2 dpm 103/mm2, p5 0.05, Mann±Whitney
test. & CLI; ~ Controls.
Fig. 6. High-resolution autoradiographs of ET receptor binding to microvessels in muscle biopsies. ETA (right) and ETB (left) receptor
binding was localized to microvessels within muscle biopsies. Middle panel shows underlying tissue stained with haematoxylin and eosin.
Scale bar 250mm.
448 J. C. S. Tsui et al.

















beneath normal intima. These results suggest that the
expression of ET receptor subtypes is changeable and
in atherosclerosis, the accumulation of foamy macro-
phages may modulate a shift in receptor subtype
expression from ETA to ETB. ETB receptors may then
act as the principle receptor involved in the progres-
sion of atherosclerosis by mediating inflammation
and possibly stimulating neovascularization.9 These
effects, in addition to vasoconstriction mediated by
both receptor subtypes, are also likely to play an
important role in chronically ischaemic muscle. Inter-
estingly, the present findings are in keeping with
experimental studies demonstrating raised ET-1 levels
in other chronically ischaemic tissue such as ischaemic
myocardium39 where upregulation of ET receptors has
also been shown to occur, but predominantly of the
ETA receptor subtype.
40
The properties of U-II are less clear. Whilst some
studies have shown that U-II has vasoconstrictor
activity on human coronary, mammary and radial
arteries, which was 50 times more potent than
ET-1,41 others have found that it has no vasoconstrict-
or action on human subcutaneous resistance arteries.16
Another recent study has demonstrated a vasodilator
effect of U-II on human pulmonary arteries and
abdominal arteries with a similar potency to the pep-
tide adrenomedullin.17 These studies suggest that
there is anatomical variation in the vasoactive effects
of U-II. U-II receptors have been identified in various
human tissues including arteries, heart, skeletal
muscle, cerebral cortex and renal cortex.41 However,
its function at these sites is unclear.
Here, U-II expression was found in both ischaemic
and control muscle biopsies, with no significant dif-
ferences. This suggests that its role in PVD is less
important than ET-1.
In conclusion, the ET-1 pathway was upregulated in
chronic lower limb ischaemia with increased protein
synthesis and receptor expression. The ETB receptor
was preferentially increased, suggesting that ET-1
may be important in the pathophysiology of PVD via
ETB-mediated effects such as inflammation and micro-
vessel constriction. U-II expression was not affected,
suggesting that this peptide may play a limited role in
PVD. Whilst the properties of U-II are not clearly
understood at present, it may be that the vasoactive
effects of other endogenous peptides such as ET-1 play
a less important role in CLI than their mitogenic, pro-
inflammatory and other properties. These findings
underscore the potential therapeutic benefits of ET
antagonism in the treatment of PVD. The role of the
two ET receptor subtypes need further investigation
and may lead to the use of subtype selective antago-
nists in the management of PVD.
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